Home Featured Page 268

Featured

Latest

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2)

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Numinus to expand state-of-the-art psychedelics research laboratory

PT234 – Christopher Solomon – Salvia as a Therapist

Better Plant Appoints Branding Expert Perry Chua as Chief Creative Officer

COMPASS Pathways plc announces financial results and business highlights for fourth...

Psychedelics Research Review: February 2021

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug...

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research...

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

Psychedelic Speech: How Drugs Disorganize Normal Communication Patterns

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on...

1...267268269...293 Page 268 of 293

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.